Dr. Kyle Hogarth & Dr. Abhinav Agrawal
A patient came to UC with a 3.5cm mass in the LUL near the aorta and other vascular structures. This patient had a previous navigation bronchoscopy resulting in insufficient tissue for tumor biomarker testing and Next-Generation Sequencing (NGS). A robotic-assisted bronchoscopy with the MONARCH® Platform was scheduled to acquire enough tissue for NGS.
The mass was located in the left upper lobe near the aorta. CT showed a possible small, very medial airway compressed by the mass traveling eccentric to the mass. A sharp turn at the distal tip would be required to align with any aspect of this mass and any tip deflection during biopsy may lead to a pathological analysis of insufficient tissue. The MONARCH® Platform was chosen for this procedure due to its control, stability, and continuous vision.
After a quick initialization, navigation to the mass location was achieved in under two minutes. A small, compressed, and inflamed airway was visible. The MONARCH® Platform scope was aligned to the mass in a controlled fashion using small micromovements. A flexible biopsy needle was used to penetrate the inflamed airway wall and create a path for radial EBUS (REBUS). REBUS confirmed an eccentric view, but because use of the mini-probe was done under live vision, the location of the mass behind the airway was able to be determined with a high degree of confidence. After aligning to the appropriate trajectory and airway insertion point, several needle biopsies were performed. A biopsy forceps was then passed through the needle hole in the airway wall to obtain large pieces of tissue. All biopsies were confirmed on ROSE as adenocarcinoma.
Tissue biopsy quality and quantity were deemed sufficient for NGS, PD-L1, and other tests. This patient had a several week delay in the care of her progressive cancer, but the oncology team was able to use these results to continue the patient’s personalized treatment plan.
"This procedure was successful because of the fine control, stability, & continuous vision of the MONARCH® Platform."
This case would have been difficult without the fine control at the scope distal tip and ability to access and hold a highly articulated position. Live, continuous vision with REBUS provided directional feedback and allowed for repeat biopsies in one location to facilitate a track to fit biopsy forceps and acquire sufficient tissue for NGS.
Dr. Hogarth is a Professor of Medicine and Director of Bronchoscopy in Chicago, IL.
Dr. Agrawal is an Interventional Pulmonary Fellow (2019-2020) in Chicago, IL
Indications for Use: The MONARCH® Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
Important Safety Statement: Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. It is uncommon for patients to experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
This document reflects the techniques, approaches and opinions of the individual physician. This Auris sponsored document is not intended to be used as a training guide. Other physicians may employ different techniques. The steps demonstrated may not be the complete steps of the procedure. Individual physician preference and experience, as well as patient needs, may dictate variation in procedure steps. Before using any medical device, review all relevant package inserts with particular attention to the indications, contraindications, warnings and precautions, and steps for use of the device(s).
Dr. Kyle Hogarth & Dr. Abhinav Agrawal are compensated by and writing on behalf of Auris Health and must present information in accordance with applicable FDA requirements.
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.